We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

18 hedge funds and large institutions have $57.1M invested in Monopar Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

53,861% more capital invested

Capital invested by funds: $106K → $57.1M (+$57M)

200% more funds holding

Funds holding: 6 → 18 (+12)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

41.96% more ownership

Funds ownership: 0.45% → 42.41% (+42%)

Holders
18
Holders Change
+12
Holders Change %
+200%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
3
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$17.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.1M
3
RCM
RA Capital Management
Massachusetts
+$8.58M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.82M
5
ACM
ADAR1 Capital Management
Texas
+$2.18M

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$4.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$23.4M +$17.6M +1,046,899 New
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$13.2M +$10.1M +599,195 New
RCM
3
RA Capital Management
Massachusetts
$11.2M +$8.58M +511,207 New
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$3.69M +$2.82M +167,892 New
ACM
5
ADAR1 Capital Management
Texas
$2.86M +$2.18M +130,037 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.24M +$948K +56,509 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$849K +$412K +24,530 +174%
BlackRock
8
BlackRock
New York
$178K +$136K +8,101 New
UBS Group
9
UBS Group
Switzerland
$141K +$99.2K +5,911 +1,154%
IC
10
Ikarian Capital
Texas
$130K +$99.1K +5,908 New
Morgan Stanley
11
Morgan Stanley
New York
$83.6K +$63.8K +3,801 New
JP Morgan Chase
12
JP Morgan Chase
New York
$44.8K +$34.2K +2,037 New
TRCT
13
Tower Research Capital (TRC)
New York
$15.3K +$11.7K +696 New
NA
14
NewEdge Advisors
Louisiana
$13.2K – – –
Wells Fargo
15
Wells Fargo
California
$5.5K -$4.2K -250 -50%
SS
16
SBI Securities
Japan
$2.2K +$1.68K +100 New
Bank of America
17
Bank of America
North Carolina
$616 +$252 +15 +115%
FDCDDQ
18
Federation des caisses Desjardins du Quebec
Quebec, Canada
$352 – – –

MNPR Hedge Fund Activity: Q4 2024 in Review

18 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2024, worth a combined $57.1M — up 53,861% from $106K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new MNPR positions and 0 closed out — a net gain of 12 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $17.6M. The largest seller was Wells Fargo, cutting an estimated $4.2K.

  • 18 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $57.1M of Monopar Therapeutics stock for Q4 2024, up 53,861% quarter-over-quarter.
  • 12 funds opened new Monopar Therapeutics positions in Q4 2024 and 0 closed out, a net change of +12 holders.
  • The largest Monopar Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $17.6M added.
  • The largest Monopar Therapeutics seller in Q4 2024 was Wells Fargo, an estimated $4.2K sold.

Based on aggregated 13F filings for Q4 2024.